Parallax Volatility Advisers, L.P. Immuno Gen, Inc. Transaction History

Parallax Volatility Advisers, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$3.67 - $4.92 $120,548 - $161,607	32,847 Added 48.91%	100,000 $384,000
Q4 2022 Feb 14, 2023	BUY	$4.55 - $6.31 $305,546 - $423,735	67,153 New	67,153 $333,000
Q2 2022 Aug 15, 2022	BUY	$3.15 - $5.76 $118,175 - $216,092	37,516 Added 97.44%	76,016 $342,000
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $164,010 - $287,980	38,500 New	38,500 $183,000
Q2 2019 Aug 14, 2019	SELL	$1.8 - $3.3 $226,200 - $414,701	-125,667 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$2.41 - $5.91 $302,857 - $742,691	125,667 New	125,667 $341,000
Q4 2018 Feb 14, 2019	SELL	$3.94 - $9.7 $111,836 - $275,334	-28,385 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$8.6 - $11.26 $244,111 - $319,615	28,385 New	28,385 $269,000
Q1 2018 May 15, 2018	SELL	$6.7 - $12.95 $102,148 - $197,435	-15,246 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$5.07 - $7.92 $77,297 - $120,748	15,246	15,246 $98,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.